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Abstract
Introduction: Black women appear to have worse outcome after diagnosis and treatment of
breast cancer. It is still unclear if this is because Black race is more often associated with known
negative prognostic indicators or if it is an independent prognostic factor. To study this, we
analyzed a patient cohort from an urban university medical center where these women made up
the majority of the patient population.
Methods: We used retrospective analysis of a prospectively collected database of breast cancer
patients seen from May 1999 to June 2006. Time to recurrence and survival were analyzed using
the Kaplan-Meier method, with statistical analysis by chi-square, log rank testing, and the Cox
regression model.
Results: 265 female patients were diagnosed with breast cancer during the time period. Fifty
patients (19%) had pure DCIS and 215 patients (81%) had invasive disease. Racial and ethnic
composition of the entire cohort was as follows: Black (N = 150, 56.6%), Hispanic (N = 83, 31.3%),
Caucasian (N = 26, 9.8%), Asian (N = 4, 1.5%), and Arabic (N = 2, 0.8%). For patients with invasive
disease, independent predictors of poor disease-free survival included tumor size, node-positivity,
incompletion of adjuvant therapy, and Black race. Tumor size, node-positivity, and Black race were
independently associated with disease-specific overall survival.
Conclusion: Worse outcome among Black women appears to be independent of the usual
predictors of survival. Further investigation is necessary to identify the cause of this survival
disparity. Barriers to completion of standard post-operative treatment regimens may be especially
important in this regard.
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Introduction
"Racial, ethnic, and socioeconomic disparities are
national problems that affect health care at all points in
the process." This declaration came from the first National
Healthcare Disparities Report released by the U.S. Depart-
ment of Health and Human Services in 2003, and was
supported by literature from a wide variety of medical spe-
cialties. [1] More specifically, African-American or Black
women have had historically worse outcome after treat-
ment for breast cancer when compared to their non-Black
counterparts. [2-8] A number of putative, probably inter-
related factors have been implicated to explain this dis-
crepancy including genetic background [9-12], diet and
body habitus [13-16], cultural attitudes toward cancer and
medicine in general [17-21], poverty and limited access to
healthcare [22-26], late stage at presentation[23,27,28], as
well as a various intrinsic biological properties of the pri-
mary tumor. [29-36] To try and further elucidate this
issue, we examined the outcomes for this disease within
our institution. The University Hospital in Newark, New
Jersey is a major source of healthcare for low income and
medico-economically underserved patients, the great
majority of whom are Black or Hispanic. Given the rela-
tive uniformity in socio-economic status of the patient
population, potentially valuable insight might be gained
by examining the comparative outcome of Black women
in this cohort study.
Methods
University Hospital is a tertiary care medical center that is
New Jersey's only public hospital and receives the largest
share of charity care funding of any facility in the state.
[37] Using retrospective cohort analysis of a prospectively
collected database, we examined the outcomes of treat-
ment for operable breast cancer at this institution from
May 1999 through June 2006. Patients not having surgical
resection were excluded. Race and ethnicity were classified
at initial patient registration via self-identification. The
following racial categories were utilized as per the Federal
Office of Management and Budget guidelines: American
Indian or Alaskan Native, Asian, Black or African Ameri-
can, Native Hawaiian or Other Pacific Islander, and
White. [38] Patients were also ethnically classified as His-
panic or non-Hispanic[38]; those women who were of
Black race but Hispanic ethnicity were categorized as
Black for analytic purposes (Table 1). Other patient and
tumor characteristics were collected prospectively from
patient charts and pathology reports and are summarized
in Tables 1, 2, 3, and 4. Follow up status was obtained via
physician visit notes and patient interview. Recurrences
were confirmed pathologically whenever indicated; other-
wise, a highly suggestive imaging study leading to further
treatment was used as documentation. Survival was ana-
lyzed via the method of Kaplan-Meier. [39] Death from
disease was the main endpoint (disease-specific survival).
Statistical significance was determined by chi-square anal-
ysis when examining differences in patient and tumor
characteristics between races, log rank testing for survival
analysis, and the Cox regression model for multivariate
outcome analysis. The study was performed with IRB
approval.
Results
Patient factors
Between May 1999 and June 2006, 265 women under-
went operative therapy for breast cancer at University
Hospital in Newark. Of these, 215 patients had invasive
disease (81%) and 50 patients (19%) had pure ductal-car-
cinoma-in-situ (DCIS). Racial/ethnic composition of the
cohort is listed in Table 1. Black females made up the
majority of our cohort (57%, N = 150), and all subse-
quent analyses grouped the remaining non-Black racial/
ethnic categories together (N = 115) so as to be able to
perform pair-wise comparison of factors and outcomes.
The mean age of the Black patients was 54.2 years as com-
pared to 53.6 years for the rest. Among the subset with
invasive cancers (N = 215), mean age was 54.0 years for
Black patients and 52.9 years for others. Patients under 50
years of age made up 41% of the former cohort (N = 62/
150) and 50% of the latter (N = 57/115); among the
patients with invasive tumors, these fractions were 41%
(N = 51/124) vs. 48% (N = 44/91), respectively. None of
these differences were statistically significant (Table 2).
Although definitive data on socio-economic status was
not available, we felt that health insurance status might
act as an adequate surrogate for this factor. At the time of
initial treatment, 45% (N = 118) of the entire cohort was
uninsured ("charity care"), 21% (N = 57) had Medicaid or
were covered by a Medicaid HMO, 23% (N = 61) had
Medicare, and 11% (N = 29) had private insurance. Black
patients were significantly less likely to have no insurance
(charity care) than others (35% vs 57 %, respectively, p <
.001). If Medicaid and charity care are categorized
together and compared to patients insured by Medicare or
private insurance, Black patients were still more likely
than the others to be in the latter group (40% vs 26%,
respectively, p < .05). Despite these notable race-based
discrepancies in level of insurance coverage, there was no
significant difference between the two groups in terms of
Table 1: Racial/ethnic composition.
Identifier N (%)
Black 150 (56.6%)
Hispanic (non-Black) 83 (31.3%)
Caucasian (non-Hispanic) 26 (9.8%)
Asian 4 (1.5%)
Middle-Eastern (Arabic) 2 (0.8%)World Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
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percentage of cancers found on screening mammography
vs. those discovered clinically by the patient or physician
(Table 2, p = .41).
Obesity has been linked to both a higher risk of breast
cancer diagnosis [40-42] and disease-specific mortality.
[43-48] Concordantly, the median BMI of our entire
cohort was 30 (range 16.1 – 68.8), a number that falls into
the "obese" category (Table 2). [49] Black females how-
ever, were significantly more obese than those of other
racial/ethnic groups (median BMI 31.6 vs. 29.2, p < .05).
Subset analysis, however, demonstrated that there was no
race-based difference in BMI in women younger than 45
years (30.6 for Blacks, 29.7 for others). The higher inci-
dence of obesity was mainly limited to Black women > 45
years of age (median BMI 32.0 vs 28.9 for the others, p <
.01).
Table 2: Patient factors examined by race.
Black Others p
Mean (Median) Age (yrs), all patients 54.2 (53.4) 53.6 (51.1) .70
Mean (Median) Age (yrs), invasive disease 54.0 (53.4) 52.9 (51.2) .55
% of patients ≤ 50 Y 41% (62/150) 50% (57/115) .18
Mean (Median) BMI, all patients 31.6 (30.7) 29.2 (27.9) <.05
Mean (Median) BMI, patients ≤ 45 Y 30.6 (30.6) 29.7 (29.2) .60
Mean (Median) BMI, patients > 45 Y 32.0 (30.8) 28.9 (27.5) <.01
Medical Comorbidities (≥ 1) 82/150 (55%) 48/115 (42%) <.05
Medical Comorbidities (≥ 2) 34/150 (23%) 11/115 (10%) <.01
Hypertension 69/150 (46%) 35/115 (30%) <.05
Diabetes 15/150 (10%) 15/115 (13%) .44
Cardiac disease or PVD 18/150 (12%) 6/115 (5%) .06
Renal insufficiency 4/150 (3%) 1/115 (1%) .29
Hepatitis and/or cirrhosis 6/150 (4%) 1/115 (1%) .12
Reactive airway disease/COPD 15/150 (10%) 6/115 (5%) .15
Contralateral Breast Cancer, all 8/150 (5%) 7/115 (6%) .79
Contralateral Breast Cancer, synchronous 1/150 (1%) 5/115 (4%) <.05
Contralateral Breast Cancer, metachronous 7/150 (5%) 2/115 (2%) .19
Family History of Breast Cancer, any 41/150 (27%) 25/115 (22%) .21
Family History of Breast Cancer, 1° relatives 15/41 (37%) 10/25 (40%) .92
Health insurance, Uninsured 52/150 (35%) 66/115 (57%) <.001*
Health insurance, Medicaid 38/150 (25%) 19/115 (17%)
Health insurance, Medicare 46/150 (31%) 15/115 (13%) <.05#
Health insurance, Private 14/150 (9%) 15/115 (13%)
Screening Detected, all patients 55/150 (37%) 48/115 (42%) .40
Screening Detected, invasive disease only 36/124 (29%) 31/91 (34%) .43
* Comparison of fraction of uninsured patients in each group.
# Comparison of fraction of patients who were uninsured or had Medicaid vs. those who had Medicare and/or private insurance in each group.
Table 4: Pathologic factors examined by race.
Black Other p
Mean primary tumor size (median) 3.0 cm (2.4) 3.0 cm (2.5) .92
% of tumors which were multifocal 38% (40/106) 32% (25/77) .69
% of tumors which were high grade 44% (46/104) 36% (26/73) .25
% of tumors which were ER-negative 42% (50/118) 34% (30/87) .25
% of tumors which were Her2-positive 25% (28/112) 25% (21/84) 1.00
% node-positive disease 51% (63/124) 47% (43/91) .61
Mean (median) number of harvested nodes in patients undergoing ALND 21.3 (20) 21.8 (21) .76
Mean (median) number of involved nodes in node-positive patients 5.1 (2) 4.0 (2.5) .39World Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
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Overall, Black women also had a significantly higher inci-
dence (55% vs. 42%, p < .05) of a history of at least one
of the following medical comorbidities: 1) hypertension,
2) diabetes, 3) cardiac or peripheral vascular disease, 4)
renal insufficiency, 5) hepatitis or cirrhosis, and/or 6)
reactive airway disease or chronic obstructive pulmonary
disease (COPD). More specifically, they were at higher
risk for hypertension (46% vs. 30%, p < .05) and border-
line higher risk for significant cardiac or peripheral vascu-
lar disease (12% vs. 5%, p = .06). Black women were also
more likely to be affected by two or more concomitant
comorbidities (23% vs. 10%, p < .01).
A history of contralateral breast cancer was found in 15
patients (6%). Of these, 9 were metachronous and 6 were
synchronous. There was no significant difference between
the patient subsets in the incidence of bilateral disease –
8/150 (5%) for Black women and 7/115 (6%) for others.
However, the risk of synchronous bilateral breast cancer
was higher in the non-Black patient group (p < .05, Table
2). Of the patients who had knowledge of their family his-
tory (N = 260, 98%), 25% (N = 66/260) claimed at least
one family member with a diagnosis of breast cancer.
There was no statistically significant difference in the frac-
tion of Black women with a positive family history of dis-
ease (27%, N = 41/150) as compared to women of other
races (22%, N = 25/115). Of the 66 women who did give
a positive family history, 38% (N = 25) had at least one
first-degree relative affected. Again, there was no signifi-
cant racial difference in the number of women who had at
least one affected first-degree relative vs. those in whom
the affected relative was more distant: N = 15/41 (37%)
for Black patients and N = 10/25 (40%) for others (Table
2).
Diagnosis and treatment
Among the patients with invasive disease (N = 215), only
67 (31%) had their tumors initially detected with screen-
ing mammography. The great majority of the patients pre-
sented with a self-discovered mass as the initial complaint
(N = 135, 63%). The rest had either a mass detected on
physical exam (N = 10, 5%) or persistent mastalgia as the
main complaint (N = 3, 1%). No significant racial discrep-
ancy was found in the incidence of screening-detected
cancers: 29% (36/124) for Black women compared to
34% (31/91) for others. The interval from date of initial
abnormal mammogram or breast physical exam to date of
diagnostic biopsy was not specifically examined in this
study. However, a previous report has demonstrated no
race-based differences in this time interval at our institu-
tion. [50] Excluding those patients who were diagnosed at
outside hospitals (N = 34) and those who underwent neo-
adjuvant chemotherapy (N = 34), the mean interval from
date of pathologic diagnosis to date of initial surgical
treatment was 25 days (median 22 days) for the entire
cohort. This interval was not statistically changed based
on race (median of 23 days for Black patients vs. 22 days
for the rest) or insurance status (charity care vs. Medicaid
vs. Medicare/private insurance).
Of the 50 patients with pure DCIS, 29 (58%) had breast-
conserving surgery, while 21 (42%) had mastectomy (5 of
the 21 had immediate reconstruction at the time of resec-
tion). Breast surgery in patients with invasive disease (N =
215) was as follows: local excision (N = 98, 46%), mastec-
tomy (N = 89, 41%), and mastectomy with immediate
reconstruction (N = 28, 13%). In 85 (40%) of these
patients, axillary staging was accomplished with sentinel
lymph node biopsy (SLNB) only. In the remainder of the
patients with invasive breast cancer, 61 (28%) had SLNB
and axillary lymphadenectomy (ALND), 61 (28%) had
ALND only, and 8 (4%) did not undergo an axillary stag-
ing procedure. Patterns of surgery are summarized in
Table 3. No statistically significant difference was noted in
use of breast conservation surgery based on patient race.
Indications for neoadjuvant chemotherapy were either
locally advanced or unresectable disease at presentation
or a resectable large primary tumor that precluded breast
conservation in a patient who was strongly adverse to
mastectomy. Neoadjuvant chemotherapy was given to
18% of Black females (22/124) and 13% of women of
Table 3: Patterns of Breast Surgery, Axillary Staging, and 
Adjuvant Therapy.
Disease Treatment Black Other
DCIS BCT 15/26 (58%) 14/24 (58%)
MAST 9/26 (34%) 7/24 (29%)
MAST-R 2/26 (8%) 3/24 (13%)
Invasive BCT 57/124 (46%) 41/91 (45%)
MAST 54/124 (44%) 33/91 (36%)
MAST-R 13/124 (10%) 17/91 (19%)
Invasive SLNB 51/124 (41%) 34/91 (38%)
SLNB + ALND 30/124 (24%) 31/91 (34%)
ALND 39/124 (32%) 22/91 (24%)
None 4/124 (3%) 4/91 (4%)
Invasive CT 91/124 (73%) 65/91 (71%)
RT 76/124 (61%) 54/91 (59%)
HT 67/124 (54%) 53/91 (58%)
NC 19/124 (15%) 3/91 (3%) *
Key: BCT – breast conservation therapy, MAST – mastectomy, 
MAST-R – mastectomy with reconstruction, SLNB – sentinel lymph 
node biopsy only, SLNB + ALND – sentinel lymph node biopsy and 
axillary node dissection, ALND – axillary node dissection only, CT – 
Chemotherapy offered and accepted, RT – radiation therapy offered 
and accepted, HT – Hormonal therapy offered and accepted, NC – 
noncompliance with offered adjuvant therapy.
* The difference in the incidence of noncompliance was statistically 
significant, p < .01.World Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
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other ethnicities (12/91). This difference was not statisti-
cally significant.
Histopathology
Standard prognostic factors were examined and compared
for the two groups (Table 4). Mean primary tumor size
was 3.0 cm and was the same for both subsets (median
tumor size was 2.4 cm for Black women and 2.5 cm for
others). For patients in whom this information was spec-
ified on the pathology report (N = 183), the incidence of
multifocal disease (defined as discontinuous foci of either
DCIS or invasive disease) was not significantly different
based on race, being found in 38% (40/106) of Black
patients and 32% (25/77) of the others. There was a sim-
ilarly higher fraction of Black patients with high-grade
tumors (44 vs. 36%) and with tumors that were estrogen-
receptor (ER) negative (42% vs. 34%), however, these dif-
ferences were not statistically significant. Her2 expression
was noted in 25% of both patient cohorts.
Lymph node status was also similar for Black women and
other patients. The nodal staging was technically ade-
quate; the mean and median number of total harvested
axillary nodes was approximately 21 in both groups
(Table 4). Node-positive disease was found in 51% of the
Black females and 47% of the others (p = .61). The mean
number of positive nodes in Black women was 5 com-
pared to 4 for others (median 2 vs. 2.5, respectively, p =
.39). In summary, standard primary tumor and nodal fac-
tors were statistically similar between Black and non-Black
patient subsets.
Follow-up and outcomes
Survival and outcome analysis was limited to patients
with invasive disease (N = 215). Mean follow-up time was
2.7 years. The fraction of patients receiving adjuvant ther-
apy was as follows: hormonal treatment was given to 120
patients (56%), systemic chemotherapy (either pre-oper-
atively or post-operatively) to 156 patients (73%), and
radiation therapy to 130 patients (60%). Response to neo-
adjuvant therapy was defined as a measurable decrease in
T and/or N stage after chemotherapy, as determined by
comparison of the pre-operative physical exam and radio-
logical studies with the final pathology report. For
instance, a decrease in FDG-uptake on PET scan was not
considered a response unless it was accompanied by a def-
inite decrease in size and/or significant histopathologic
necrosis of the final specimen. By this measure, there was
a notable difference between the two cohorts, i.e., only 9/
22 (41%) Black women responded, whereas 8/12 (67%)
women of other races showed a dramatic response. These
differences did not reach statistical significance (p = .15),
likely due to the small numbers involved. Compliance
with post-operative adjuvant therapy was defined as com-
pletion of recommended treatment in a timely manner
(morbidity-related delays due to wound infections or neu-
tropenia were not counted as non-compliant). With this
definition, we documented non-compliance in only 3/91
(3%) non-Black females. However, 19/124 (15%) Black
females either refused or failed to complete standard post-
operative adjuvant therapy regimens, a highly significant
disparity (Table 3, p < .01). As might be expected, failure
to complete adjuvant therapy was significantly related to
the risk of locoregional recurrence – 6/22 patients (27%)
vs. 7/193 patients (4%), p < .001. Concordantly, Black
women were significantly more likely to have a locore-
gional recurrence within the time frame of our follow-up
than those of other races (10% vs. 1%, p < .01, Table 5).
Factors not predictive of either disease-free or overall sur-
vival by univariate analysis included presence of two or
more comorbidities, body mass index (BMI) > or ≤ 30,
lack of insurance, tumor grade, and hormone receptor sta-
tus. Univariate factors predicting worse disease-free sur-
vival (DFS) included increasing tumor size, node-
positivity, Black vs. other race (Figure 1), and non-compli-
ance with adjuvant treatment (Figure 2). When subjected
to multivariate analysis, all remained independent predic-
tors of disease-free survival (Table 6). Univariate predic-
tors of overall disease-specific survival included tumor
size, node-positivity, and Black vs. other race (Figure 3).
Non-compliance was not predictive when disease-specific
death was the endpoint (p = .13 and p = .64, respectively).
In multivariate analysis, primary tumor size, node-posi-
tivity, and Black race were all independent predictors of
overall breast cancer specific survival to varying degrees
(Table 6).
Discussion
Race-based analysis of healthcare outcomes has long been
a source of controversy. Complicating the matter is the
impossibility of establishing absolutely clear ethnic, cul-
tural, or genetic boundaries that allow definitive categori-
zation of patients based on the concept of "race." Some
authors have considered the present boundaries arbitrary
at best, and even fraught with potential moral ambiguity,
if one accepts the concept of race as a "societal con-
struct."[51,52] Others, however, have considered these
categorizations informative, arguing that racial differences
in disease course and response to therapy empirically exist
and may have a genetic basis. [53] Clearly, the main issue
is the relationship of "race" to other known factors of poor
prognosis, that is, are they independent or simply associ-
ative? In this study, we attempt to examine this issue
within our database of breast cancer patients. We
acknowledge some limitations to this analysis. Our
patient population was largely Black and Hispanic; Cauca-
sians and Asians made up only about 10% of the cohort.
Thus, when we compare Black patients to non-Black
patients, this is largely a comparison of the former groupWorld Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
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to non-Black Hispanics. Secondly, we realize that our fol-
low up time is relatively short for a study of breast cancer
outcomes. Despite these caveats, however, some interest-
ing results are evident.
Within the context of our largely urban, poor patient
cohort, Black women tended to have better financial
healthcare coverage than those of other races. Over half of
them had some form of insurance compared to only
about a third of the others. Nevertheless, most patients
were uninsured or had Medicaid, and it was not surprising
that a minority of women in both groups had screening
detected cancers (29% of Black women and 34% of oth-
ers, p = .43, Table 2). Although the median age of the two
groups was similar, Black women were more likely to have
one or more medical comorbidities such as hypertension
or diabetes and also tended to be more obese (albeit, the
latter finding was mainly limited to post-menopausal
women, Table 2). Body mass index and the presence of
comorbidities were not significant predictors of disease-
free or overall survival, however.
There were no race-based differences in time intervals to
diagnosis and start of treatment. In a previous study from
our group that included patients from the present cohort,
we examined the time interval between date of initial sus-
picious mammogram and/or physical exam and final
pathologic diagnosis (the diagnostic interval) and found
this to be statistically equivalent among women of differ-
ent races. [50] In the present study, we further demon-
strated no racial difference in time to definitive surgery
after the pathologic diagnosis of breast cancer had been
established. The nature of the subsequent surgical treat-
ment and pathology results was also statistically similar
between racial groups (Tables 3 and 4).
Recent data has suggested that minority women (Blacks
especially, but Hispanics as well) were significantly less
likely to be offered appropriate postoperative therapy
than Caucasians. [54] In our cohort, we found that adju-
vant radiation and chemotherapy were offered and given
to a similar fraction of patients in each group (Tables 3).
Other studies have noted that chemotherapy doses are
often significantly lower in Black women and have impli-
Table 5: Locoregional and distant recurrence data between 
racial groups.
Recurrence type Black Other p
None, N (%) 101/124 (81%) 85/91 (93%) .01
Isolated locoregional 6/124 (5%) 1/91 (1%) .13
Any locoregional 12/124 (10%) 1/91 (1%) <.01
Distant 18/124 (15%) 5/91 (5%) .03
Disease-free survival was significantly worse in Black women compared to those of other races (p < .01) Figure 1
Disease-free survival was significantly worse in Black women compared to those of other races (p < .01).World Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
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cated this factor as a source of prognostic disparity. [55]
We could not address this issue, unfortunately, as infor-
mation on specific doses was not recorded in our data-
base. However, one striking feature of our patient
population was the rate of noncompliance with post-
operative adjuvant therapy (either outright refusal or fail-
ure to complete therapy) in Black women. This was noted
in 15% of this group but only 3% of women of other races
(Table 3, p < .01). This racial discrepancy in the fidelity of
post-operative follow-up has been previously noted by
other authors and implicated as a possible cause of out-
come disparities. [25]
Black race along with expected factors such as tumor size
and lymph node status were significant independent
determinants of disease-free and overall survival (Table
6). Factors such as hormone receptor negativity and high
grade/poor tumor differentiation did not reach statistical
significance, a finding we ascribe to our relatively small
data set and follow up time. Insurance status, presence of
comorbidities, and body mass index were not significant
predictors of outcome. Not surprisingly[25,56], lack of
compliance with postoperative adjuvant therapy had sig-
nificant negative impact on the chance of disease-free sur-
vival in both univariate and multivariate analyses (Table
6). Interestingly, multivariate analysis of overall disease-
specific survival demonstrated only tumor size, nodal sta-
tus, and Black race to be significant. When examining the
results of the Cox regression analysis, Black race was asso-
ciated with only a slightly worse prognosis based on haz-
ard ratios (38% higher risk of disease recurrence and only
12% higher risk of death due to breast cancer). However,
noncompliance with adjuvant therapy conferred a greater
than 4× higher risk of disease recurrence – significantly
greater than even tumor size (HR 1.1) or nodal status (HR
1.5, Table 6). Given the high correlation of Black race to
noncompliance, we are therefore somewhat circumspect
as to the ultimate relation between these factors and over-
all survival. Although noncompliance appeared to lose
significance in the Cox regression analysis of overall sur-
vival, we suspect that this is mainly a function of follow
up time, with eventual deaths from recurrence being inev-
itable.
We are uncertain as to why Black women in this study had
such a high rate of failure to complete adjuvant therapy.
Obviously, postoperative treatment is a difficult process
that requires serious and time-intensive patient commit-
ment. The more frequent utilization of less-than-radical
surgery, although welcome, has only made this more
problematic since conservative resection is frequently
combined with more rigorous and demanding adjuvant
Refusal or failure to complete adjuvant therapy regimens was associated with significantly worse rates of disease-free survival  (p < .001) Figure 2
Refusal or failure to complete adjuvant therapy regimens was associated with significantly worse rates of dis-
ease-free survival (p < .001).World Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
Page 8 of 10
(page number not for citation purposes)
treatment regimens. We can speculate on a number of rea-
sons why Black women may be less compliant with these
demands. Although the great majority of our patient
cohort could easily be described as underserved, there was
little question that Black patients were not over-repre-
sented in this regard, and in fact, were more likely to have
some form of insurance than those of other groups (Table
2). Furthermore, there were many more English-speaking
patients in this racial group, thus one could reasonably
surmise that language was not a significant barrier to
appropriate post-operative treatment. Other more formi-
dable barriers may exist, however. Historical data suggests
that healthcare in the Black community may be under-
mined by mistrust and/or lack of faith in the medical
establishment, much of it stemming from revelations of
the Tuskegee syphilis experiments in which untreated
Black men were unknowing subjects of a natural history
study by the United States Public Health Service. This atti-
tude may be more pervasive than previously realized,
especially among those of lower socioeconomic status
[57-59]. Finally, although clearly important, we cannot
comment on the levels of familial and social support
available to patients during their treatment.
In conclusion, although we found Black race to be a pre-
dictor of poor outcome after treatment for breast cancer, it
had a relatively small effect as an independent factor. Fail-
ure to follow through with postoperative adjuvant therapy
was the most important factor in determining recurrence-
free survival, and this factor was significantly more preva-
lent in our Black patient cohort. Further research should
be aimed at seeing if this phenomenon is more generally
Black race was a significant predictor of disease-specific survival on both univariate (p < .01) and multivariate analyses Figure 3
Black race was a significant predictor of disease-specific survival on both univariate (p < .01) and multivariate 
analyses.
Table 6: Multivariate analysis of factors associated with disease-free survival and disease-specific overall survival.
Factor DFS (p) HR (95% CI) OS (p) HR (95% CI)
Tumor size .03 1.1 (1.0 – 1.2) <.01 1.2 (1.1 – 1.3)
Node-positive disease .04 1.5 (1.0 – 2.3) .02 2.2 (1.1 – 4.5)
Black race .01 0.38 (0.15 – 0.95) .03 0.12 (0.02 – 1.0)
Compliance with adjuvant therapy <.01 4.1 (1.8 – 9.7) NSWorld Journal of Surgical Oncology 2008, 6:26 http://www.wjso.com/content/6/1/26
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observed, examining reasons why this may occur, and
implementing potential solutions. In this regard, use of
patient navigators may be a promising intervention.
[60,61] It is also imperative that larger prospective studies
continue to identify and address the socio-cultural and/or
biologic factors that continue to cause racial discrepancies
in cancer outcome.
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